Clinical and prognostic value of parameters of cytokine regulation in oxygen-dependent patients with the coronavirus disease COVID-19
DOI:
https://doi.org/10.14739/2310-1237.2023.2.283531Keywords:
coronavirus disease, COVID-19, viral infection, cytokines, “cytokine storm”, prognosisAbstract
Aim of the work is to find out the clinical and prognostic significance of cytokine regulation parameters in oxygen-dependent patients with COVID-19 coronavirus disease in dynamics of the disease.
Material and methods. 78 oxygen-dependent patients with COVID-19 aged from 52 to 84 years were examined. All patients were examined and treated in accordance with the regulations in force at the relevant time. The patients were divided into groups: I group – 38 patients who recovered; II group – 40 patients with fatal outcome of the disease. In the blood serum of patients with COVID-19 and 20 healthy individuals, were determined by enzyme immunoassay the content of interleukin (IL) IL-2 (Elabscience, USA), IL-4 (Affymetrix eBioscience, Austria), IL-6 (Invitrogen, Austria), monocyte chemotactic protein-1 (MCP-1) (Elabscience, USA). Statistical processing was performed in the Statistica 13 for Windows program (StatSoft Inc., No. JPZ804I382130ARCN10-J).
Results. The content of IL-2 in the blood serum of oxygen-dependent patients with COVID-19 of both groups was significantly higher (p < 0.001) than in healthy individuals. IL-2 content was higher in patients of II group (p < 0.001) than in patients of I group. In dynamics, a further increase in content of IL-2 was noted in patients of the II group (р < 0.05). The diagnostic significance has been established of the increased level of IL-2 in assessing the high probability of the development of a fatal outcome of the disease during hospitalization (AUC = 0.698, p = 0.030) and in the dynamics of treatment (AUC = 0.745, p = 0.015). The content of IL-6 in the blood serum of oxygen-dependent patients with COVID-19 of both groups was also significantly higher (p < 0.001) than in healthy individuals. However, the level of increase of this cytokine at the time of hospitalization did not have prognostic value regarding the risk of fatal outcome (AUC = 0.539, p = 0.562). In the dynamics of treatment, the content of IL-6 in blood serum continued to increase in patients of the II group (p < 0.01). During this period of observation, a threshold level of increase IL-6 level was established, which indicates a high probability of the development of a fatal outcome in these patients (AUC = 0.850, p < 0.001). The content of chemokine MCP-1 in blood serum at the time of hospitalization in patients of both groups was higher (p < 0.01) than in healthy people. At the same time, the content of MCP-1 in patients of the II group was higher (p < 0.05) than in the patients of the I group. The diagnostic significance of the increased level of MCP-1 was established, which indicated a high probability of the development of a fatal outcome during hospitalization. In dynamics, there was a tendency (p > 0.05) to decrease its content (p > 0.05), however, during this period of observation, MCP-1 did not have prognostic value. IL-4 turned out to be uninformative in prognostic terms for determining the probability of a fatal outcome of COVID-19.
Conclusions. Changes in the parameters of cytokine regulation in patients with COVID-19 during the development of oxygen dependence are characterized by a significant increase content of IL-2, IL-6 and chemokine MCP-1 in blood serum. The level of increase of these cytokines has diagnostic value in determining the high probability of the development of a fatal outcome of the disease at certain stages of observation.
References
Montazersaheb, S., Hosseiniyan Khatibi, S. M., Hejazi, M. S., Tarhriz, V., Farjami, A., Ghasemian Sorbeni, F., Farahzadi, R., & Ghasemnejad, T. (2022). COVID-19 infection: an overview on cytokine storm and related interventions. Virology journal, 19(1), 92. https://doi.org/10.1186/s12985-022-01814-1
Grasselli, G., Tonetti, T., Filippini, C., Slutsky, A. S., Pesenti, A., & Ranieri, V. M. (2021). Pathophysiology of COVID-19-associated acute respiratory distress syndrome - Authors' reply. The Lancet. Respiratory medicine, 9(1), e5-e6. https://doi.org/10.1016/S2213-2600(20)30525-7
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
Ragab, D., Salah Eldin, H., Taeimah, M., Khattab, R., & Salem, R. (2020). The COVID-19 Cytokine Storm; What We Know So Far. Frontiers in immunology, 11, 1446. https://doi.org/10.3389/fimmu.2020.01446
Cherkaskyi, V. V., Riabokon, O. V., & Riabokon, Yu. Yu. (2023). The clinical and prognostic role of changes in parameters of the hemostasis system and C-reactive protein in the development of thrombotic complications in oxygen-dependent patients with coronavirus disease (COVID-19). Pathologia, 20(1), 27-35. https://doi.org/10.14739/2310-1237.2023.1.274921
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020). The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity reviews, 19(6), 102537. https://doi.org/10.1016/j.autrev.2020.102537
Yang, M. (2020). Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3527420
Tavakolpour, S., Rakhshandehroo, T., Wei, E. X., & Rashidian, M. (2020). Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunology letters, 225, 31-32. https://doi.org/10.1016/j.imlet.2020.06.013
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223), 497-506. https://doi.org/10.1016/s0140-6736(20)30183-5
Barton, L. M., Duval, E. J., Stroberg, E., Ghosh, S., & Mukhopadhyay, S. (2020). COVID-19 Autopsies, Oklahoma, USA. American journal of clinical pathology, 153(6), 725-733. https://doi.org/10.1093/ajcp/aqaa062
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of clinical investigation, 130(5), 2620-2629. https://doi.org/10.1172/jci137244
Tufan, A., Avanoğlu Güler, A., & Matucci-Cerinic, M. (2020). COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turkish journal of medical sciences, 50(SI-1), 620-632. https://doi.org/10.3906/sag-2004-168
Mangalmurti, N., & Hunter, C. A. (2020). Cytokine Storms: Understanding COVID-19. Immunity, 53(1), 19-25. https://doi.org/10.1016/j.immuni.2020.06.017
Park, M. D. (2020). Macrophages: a Trojan horse in COVID-19? Nature reviews immunology, 20(6), 351. https://doi.org/10.1038/s41577-020-0317-2
Kimura, A., & Kishimoto, T. (2010). IL-6: Regulator of Treg/Th17 balance. European journal of immunology, 40(7), 1830-1835. https://doi.org/10.1002/eji.201040391
Jones, B. E., Maerz, M. D., & Buckner, J. H. (2018). IL-6: a cytokine at the crossroads of autoimmunity. Current opinion in immunology, 55, 9-14. https://doi.org/10.1016/j.coi.2018.09.002
Rostamian, A., Ghazanfari, T., Arabkheradmand, J., Edalatifard, M., Ghaffarpour, S., Salehi, M. R., Raeeskarami, S. R., Mahmoodi Aliabadi, M., Rajabnia Chenary, M., Mirsharif, E. S., Jamali, D., Sattarian, M. R., Najafizadeh, R., Hosseinieselki Sari, S., Jafarpour, S., Nezhadseifi, E., Movasseghi, S., Baharvand, E., Beiranvand, S., Roomi, A., & Naghizadeh, M. M. (2020). Interleukin-6 as a Potential Predictor of COVID-19 Disease Severity in Hospitalized Patients and its Association with Clinical Laboratory Routine Tests. Immunoregulation, 29-36. https://doi.org/10.32598/immunoregulation.3.1.4
Coomes, E. A., & Haghbayan, H. (2020). Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis. Reviews in medical virology, 30(6), 1-9. https://doi.org/10.1002/rmv.2141
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine, 46(5), 846-848. https://doi.org/10.1007/s00134-020-05991-x
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395(10223), 507-513. https://doi.org/10.1016/s0140-6736(20)30211-7
Liu, F., Li, L., Xu, M., Wu, J., Luo, D., Zhu, Y., Li, B., Song, X., & Zhou, X. (2020). Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of clinical virology, 127, 104370. https://doi.org/10.1016/j.jcv.2020.104370
Ulhaq, Z. S., & Soraya, G. V. (2020). Interleukin-6 as a potential biomarker of COVID-19 progression. Médecine et maladies infectieuses, 50(4), 382-383. https://doi.org/10.1016/j.medmal.2020.04.002
Fajgenbaum, D. C., & June, C. H. (2020). Cytokine Storm. New England journal of medicine, 383(23), 2255-2273. https://doi.org/10.1056/nejmra2026131
Chi, Y., Ge, Y., Wu, B., Zhang, W., Wu, T., Wen, T., Liu, J., Guo, X., Huang, C., Jiao, Y., Zhu, F., Zhu, B., & Cui, L. (2020). Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China. The Journal of infectious diseases, 222(5), 746-754. https://doi.org/10.1093/infdis/jiaa363
Hu, B., Huang, S., & Yin, L. (2020). The cytokine storm and COVID‐19. Journal of medical virology, 93(1), 250-256. https://doi.org/10.1002/jmv.26232
Xu, Z.-S., Shu, T., Kang, L., Wu, D., Zhou, X., Liao, B.-W., Sun, X.-L., Zhou, X., & Wang, Y.-Y. (2020). Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. Signal transduction and targeted therapy, 5(1), 100. https://doi.org/10.1038/s41392-020-0211-1
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., Mantovani, A., Matsushima, K., Murphy, P. M., Nibbs, R., Nomiyama, H., Power, C. A., Proudfoot, A. E. I., Rosenkilde, M. M., Rot, A., ... Zlotnik, A. (2013). International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. Pharmacological reviews, 66(1), 1-79. https://doi.org/10.1124/pr.113.007724
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009). Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. Journal of interferon & cytokine research, 29(6), 313-326. https://doi.org/10.1089/jir.2008.0027
Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., Guo, D., Hu, W., Yang, J., Tang, Z., Wu, H., Lin, Y., Zhang, M., Zhang, Q., Shi, M., Liu, Y., Zhou, Y., Lan, K., & Chen, Y. (2020). Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging microbes & infections, 9(1), 761-770. https://doi.org/10.1080/22221751.2020.1747363
Chu, H., Chan, J. F.-W., Wang, Y., Yuen, T. T.-T., Chai, Y., Hou, Y., Shuai, H., Yang, D., Hu, B., Huang, X., Zhang, X., Cai, J.-P., Zhou, J., Yuan, S., Kok, K.-H., To, K. K.-W., Chan, I. H.-Y., Zhang, A. J., Sit, K.-Y., ... Yuen, K.-Y. (2020). Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. Clinical infectious diseases, 71(6), 1400-1409. https://doi.org/10.1093/cid/ciaa410
Lin, L., Lu, L., Cao, W., & Li, T. (2020). Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerging microbes & infections, 9(1), 727-732. https://doi.org/10.1080/22221751.2020.1746199
Xi, X., Guo, Y., Zhu, M., Wei, Y., Li, G., Du, B., & Wang, Y. (2021). Higher expression of monocyte chemotactic protein 1 in mild COVID-19 patients might be correlated with inhibition of Type I IFN signaling. Virology journal, 18(1). https://doi.org/10.1186/s12985-020-01478-9
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., Tai, Y., Bai, C., Gao, T., Song, J., Xia, P., Dong, J., Zhao, J., & Wang, F.-S. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet. Respiratory Medicine, 8(4), 420-422. https://doi.org/10.1016/s2213-2600(20)30076-x
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021). Correction: The signal pathways and treatment of cytokine storm in COVID-19. Signal transduction and targeted therapy, 6(1), 326. https://doi.org/10.1038/s41392-021-00744-8
Shi, H., Wang, W., Yin, J., Ouyang, Y., Pang, L., Feng, Y., Qiao, L., Guo, X., Shi, H., Jin, R., & Chen, D. (2020). The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia. Cell death & disease, 11(6). https://doi.org/10.1038/s41419-020-2636-4
Qu, R., Ling, Y., Zhang, Y., Wei, L., Chen, X., Li, X., Liu, X., Liu, H., Guo, Z., Ren, H., & Wang, Q. (2020). Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19. Journal of medical virology, 92(9), 1533-1541. https://doi.org/10.1002/jmv.25767
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323(11), 1061. https://doi.org/10.1001/jama.2020.1585
Al‐Saadi, E. A. K. D., & Abdulnabi, M. A. (2021). Hematological changes associated with COVID‐19 infection. Journal of clinical laboratory analysis, 36(1), e24064. https://doi.org/10.1002/jcla.24064
Pasrija, R., & Naime, M. (2022). Resolving the equation between mucormycosis and COVID-19 disease. Molecular biology reports, 49(4), 3349-3356. https://doi.org/10.1007/s11033-021-07085-3
Wong, C. K., Lam, C. W., Wu, A. K., Ip, W. K., Lee, N. L., Chan, I. H., Lit, L. C., Hui, D. S., Chan, M. H., Chung, S. S., & Sung, J. J. (2004). Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical and experimental immunology, 136(1), 95-103. https://doi.org/10.1111/j.1365-2249.2004.02415.x
Bortolotti, D., Gentili, V., Rizzo, S., Schiuma, G., Beltrami, S., Strazzabosco, G., Fernandez, M., Caccuri, F., Caruso, A., & Rizzo, R. (2021). TLR3 and TLR7 RNA Sensor Activation during SARS-COV-2 Infection. Microorganisms, 9(9), 1820. https://doi.org/10.3390/microorganisms9091820
Pacheco-Hernández, L. M., Ramírez-Noyola, J. A., Gómez-García, I. A., Ignacio-Cortés, S., Zúñiga, J., & Choreño-Parra, J. A. (2022). Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza. Journal of interferon & cytokine research, 42(8), 369-392. https://doi.org/10.1089/jir.2022.0029
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
